These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

278 related articles for article (PubMed ID: 30770859)

  • 1. Aberrant Wnt signaling in multiple myeloma: molecular mechanisms and targeting options.
    van Andel H; Kocemba KA; Spaargaren M; Pals ST
    Leukemia; 2019 May; 33(5):1063-1075. PubMed ID: 30770859
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Multiple myeloma: signaling pathways and targeted therapy.
    Lu Q; Yang D; Li H; Niu T; Tong A
    Mol Biomed; 2024 Jul; 5(1):25. PubMed ID: 38961036
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Future of Personalized Therapy Targeting Aberrant Signaling Pathways in Multiple Myeloma.
    Anwer F; Gee KM; Iftikhar A; Baig M; Russ AD; Saeed S; Zar MA; Razzaq F; Carew J; Nawrocki S; Al-Kateb H; Cavalcante Parr NN; McBride A; Valent J; Samaras C
    Clin Lymphoma Myeloma Leuk; 2019 Jul; 19(7):397-405. PubMed ID: 31036508
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Dual role of signaling pathways in myeloma requires cell type-specific targeting of ligand-receptor interactions.
    Hernandez-Lopez P; Vijaykumar T; Anand P; Auclair D; Frede J; Knoechel B; Lohr JG
    Blood Adv; 2024 Jun; 8(12):3173-3185. PubMed ID: 38603572
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The Wnt signaling pathway in major depressive disorder: A systematic review of human studies.
    Sanchez-Ruiz JA; Treviño-Alvarez AM; Zambrano-Lucio M; Lozano Díaz ST; Wang N; Biernacka JM; Tye SJ; Cuellar-Barboza AB
    Psychiatry Res; 2024 Sep; 339():115983. PubMed ID: 38870775
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Doubling Down on Wnt Signaling to Overcome Myeloma Bone Disease.
    Delgado-Calle J; Roodman GD
    J Bone Miner Res; 2023 Jun; 38(6):812-813. PubMed ID: 37277117
    [No Abstract]   [Full Text] [Related]  

  • 7. Synergistic Efficacy of the Demethylation Agent Decitabine in Combination With the Protease Inhibitor Bortezomib for Treating Multiple Myeloma Through the Wnt/β-Catenin Pathway.
    Jin Y; Xu L; Wu X; Feng J; Shu M; Gu H; Gao G; Zhang J; Dong B; Chen X
    Oncol Res; 2019 Jun; 27(6):729-737. PubMed ID: 30837032
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The emerging role of exosomes in multiple myeloma.
    Moloudizargari M; Abdollahi M; Asghari MH; Zimta AA; Neagoe IB; Nabavi SM
    Blood Rev; 2019 Nov; 38():100595. PubMed ID: 31445775
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Biology and therapy of multiple myeloma.
    Joshua DE; Bryant C; Dix C; Gibson J; Ho J
    Med J Aust; 2019 May; 210(8):375-380. PubMed ID: 31012120
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Relapsed refractory multiple myeloma: a comprehensive overview.
    Bazarbachi AH; Al Hamed R; Malard F; Harousseau JL; Mohty M
    Leukemia; 2019 Oct; 33(10):2343-2357. PubMed ID: 31455853
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Multiple Roles of sFRP2 in Cardiac Development and Cardiovascular Disease.
    Wu Y; Liu X; Zheng H; Zhu H; Mai W; Huang X; Huang Y
    Int J Biol Sci; 2020; 16(5):730-738. PubMed ID: 32071544
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Precision medicine for human cancers with Notch signaling dysregulation (Review).
    Katoh M; Katoh M
    Int J Mol Med; 2020 Feb; 45(2):279-297. PubMed ID: 31894255
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Dkk (Dickkopf) Proteins.
    Baetta R; Banfi C
    Arterioscler Thromb Vasc Biol; 2019 Jul; 39(7):1330-1342. PubMed ID: 31092014
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Targeting the Wnt/β-catenin signaling pathway in cancer.
    Zhang Y; Wang X
    J Hematol Oncol; 2020 Dec; 13(1):165. PubMed ID: 33276800
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Multiple myeloma: Every year a new standard?
    Rajkumar SV
    Hematol Oncol; 2019 Jun; 37 Suppl 1(Suppl 1):62-65. PubMed ID: 31187526
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Adipose tissue-derived WNT5A regulates vascular redox signaling in obesity via USP17/RAC1-mediated activation of NADPH oxidases.
    Akoumianakis I; Sanna F; Margaritis M; Badi I; Akawi N; Herdman L; Coutinho P; Fagan H; Antonopoulos AS; Oikonomou EK; Thomas S; Chiu AP; Chuaiphichai S; Kotanidis CP; Christodoulides C; Petrou M; Krasopoulos G; Sayeed R; Lv L; Hale A; Naeimi Kararoudi M; McNeill E; Douglas G; George S; Tousoulis D; Channon KM; Antoniades C
    Sci Transl Med; 2019 Sep; 11(510):. PubMed ID: 31534019
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Sfrp5/Wnt Pathway: A Protective Regulatory System in Atherosclerotic Cardiovascular Disease.
    Tong S; Ji Q; Du Y; Zhu X; Zhu C; Zhou Y
    J Interferon Cytokine Res; 2019 Aug; 39(8):472-482. PubMed ID: 31199714
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Lgr4 promotes aerobic glycolysis and differentiation in osteoblasts via the canonical Wnt/β-catenin pathway.
    Yang YY; Zhou YM; Xu JZ; Sun LH; Tao B; Wang WQ; Wang JQ; Zhao HY; Liu JM
    J Bone Miner Res; 2021 Aug; 36(8):1605-1620. PubMed ID: 33950533
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The Landscape of Signaling Pathways and Proteasome Inhibitors Combinations in Multiple Myeloma.
    Paradzik T; Bandini C; Mereu E; Labrador M; Taiana E; Amodio N; Neri A; Piva R
    Cancers (Basel); 2021 Mar; 13(6):. PubMed ID: 33799793
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Role of the RANK/RANKL/OPG and Wnt/β-Catenin Systems in CKD Bone and Cardiovascular Disorders.
    Carrillo-López N; Martínez-Arias L; Fernández-Villabrille S; Ruiz-Torres MP; Dusso A; Cannata-Andía JB; Naves-Díaz M; Panizo S;
    Calcif Tissue Int; 2021 Apr; 108(4):439-451. PubMed ID: 33586001
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.